Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: A cross-sectional study

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Yasin, Abeer ^a   Liu, Daisy ^a   Chau, Luan ^b   Madrenas, Joaquín ^b,c   Filler, Guido ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Calcium phosphate product; Chronic kidney disease; Fibroblast growth factor 23; Parathyroid hormone; Renal osteodystrophy

Indexed keywords

25 HYDROXYVITAMIN D; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BICARBONATE; BIOLOGICAL MARKER; CALCITRIOL; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM PHOSPHATE; CITRATE SODIUM; CORTICOSTEROID; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; POTASSIUM; VITAMIN D DERIVATIVE; FIBROBLAST GROWTH FACTOR;

ADOLESCENT; AGE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BONE METABOLISM; CALCIUM BLOOD LEVEL; CHILD; CHRONIC KIDNEY DISEASE; CORTICOSTEROID THERAPY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY TUBULE ACIDOSIS; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; RENAL OSTEODYSTROPHY; SCHOOL CHILD; VITAMIN BLOOD LEVEL; ADULT; BLOOD; CANADA; CHRONIC KIDNEY FAILURE; PRESCHOOL CHILD; PREVALENCE; RISK ASSESSMENT;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CALCIUM PHOSPHATES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; ONTARIO; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; YOUNG ADULT;

MLCS; MLOWN;

EID: 84873734828     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-39     Document Type: Article

References (29)

1. Regulation of fibroblast growth factor-23 in chronic kidney disease. Westerberg PA, Linde T, Wikstrom B, Ljunggren O, Stridsberg M, Larsson TE, Nephrol Dial Transplant 2007 22 3202 3207 10.1093/ndt/gfm347 17567652 (Pubitemid 350202543)
2. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Evenepoel P, Meijers B, Viaene L, Bammens B, Claes K, Kuypers D, Vanderschueren D, Vanrenterghem Y, Clin J Am Soc Nephrol 2010 5 1268 1276 10.2215/CJN.08241109 20448073
3. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K, Bone 2009 45 1161 1168 10.1016/j.bone.2009.08.008 19679205
4. FGF-23 is associated with cardiac troponin T and mortality in hemodialysis patients. Holden RM, Beseau D, Booth SL, Adams MA, Garland JS, Morton RA, Collier CP, Foley RN, Hemodial Int 2011 in press
5. Vascular calcification in chronic renal failure. Goodman WG, Lancet 2001 358 1115 1116 10.1016/S0140-6736(01)06299-7 11597661 (Pubitemid 32971840)
6. Cardiovascular calcifications in pediatric patients receiving maintenance dialysis. Sheth RD, Perez MD, Goldstein SL, Pediatr Nephrol 2003 18 810 813 10.1007/s00467-003-1156-7 12774220 (Pubitemid 36949969)
7. Challenges in pediatric transplantation: the impact of chronic kidney disease and cardiovascular risk factors on long-term outcomes and recommended management strategies. Filler G, Pediatr Transplant 2011 15 25 31 10.1111/j.1399-3046.2010.01439.x 21155958
8. Coronary calcifications in end-stage renal disease patients: a new link between osteoprotegerin, diabetes and body mass index? Cianciolo G, La Manna G, Donati G, Persici E, Dormi A, Cappuccilli ML, Corsini S, Fattori R, Russo V, Nastasi V, Coli L, Wratten M, Stefoni S, Blood Purif 2010 29 13 22 10.1159/000245042 19816015
9. Plasma levels of fibroblast growth factor-23 and mineral metabolism in diabetic and non-diabetic patients on chronic hemodialysis. Kojima F, Uchida K, Ogawa T, Tanaka Y, Nitta K, Int Urol Nephrol 2008 40 1067 1074 10.1007/s11255-008-9462-4 18791804
10. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke HD, Choukroun G, Drueke TB, Massy ZA, Osteoporos Int 2011 in press
11. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB, N Engl J Med 2000 34 1478 83 (Pubitemid 30318271)
12. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Mirza MA, Larsson A, Lind L, Larsson TE, Atherosclerosis 2009 205 385 390 10.1016/j.atherosclerosis.2009.01.001 19181315
13. The potential roles of FGF23 and Klotho in the prognosis of renal and cardiovascular diseases. Bernheim J, Benchetrit S, Nephrol Dial Transplant 2011 26 2433 2438 10.1093/ndt/gfr208 21543658
14. Impaired GFR is the most important determinant for FGF-23 increase in chronic kidney disease. Filler G, Liu D, Huang SH, Casier S, Chau LA, Madrenas J, Clin Biochem 2011 44 435 437 10.1016/j.clinbiochem.2011.01.009 21291879
15. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M, J Am Soc Nephrol 2005 16 2205 2215 10.1681/ASN.2005010052 15917335 (Pubitemid 41716454)
16. Cross Talk Between the Renin-Angiotensin-Aldosterone System and Vitamin D-FGF-23-klotho in Chronic Kidney Disease. de Borst MH, Vervloet MG, Ter Wee PM, Navis G, J Am Soc Nephrol 2011 22 1603 1609 10.1681/ASN.2010121251 21852584
17. The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. Bacchetta J, Dubourg L, Harambat J, Ranchin B, Abou-Jaoude P, Arnaud S, Carlier MC, Richard M, Cochat P, J Clin Endocrinol Metab 2010 95 1741 1748 10.1210/jc.2009-1576 20157196
18. Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Srivaths PR, Goldstein SL, Silverstein DM, Krishnamurthy R, Brewer ED, Pediatr Nephrol 2011 26 945 951 10.1007/s00467-011- 1822-0 21359960
19. Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Ix JH, Shlipak MG, Wassel CL, Whooley MA, Nephrol Dial Transplant 2010 25 993 997 10.1093/ndt/gfp699 20037168
20. Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula? Filler G, Lepage N, Pediatr Nephrol 2003 18 981 985 10.1007/s00467-003-1271-5 12920638 (Pubitemid 37236209)
21. Should we consider MMF therapy after rituximab for nephrotic syndrome? Filler G, Huang SH, Sharma AP, Pediatr Nephrol 2011 26 1759 62 10.1007/s00467-011-1894-x 21533869
22. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S, J Clin Endocrinol Metab 2002 87 4957 4960 10.1210/jc.2002-021105 12414858 (Pubitemid 35316332)
23. Prevalence of complications in children with chronic kidney disease according to KDOQI. Wong H, Mylrea K, Feber J, Drukker A, Filler G, Kidney Int 2006 70 585 590 16788689 (Pubitemid 44141587)
24. A prospective study of fibroblast growth factor-23 in children with chronic kidney disease. Magnusson P, Hansson S, Swolin-Eide D, Scand J Clin Lab Invest 2010 70 15 20 19929273
25. Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease. Siomou E, Challa A, Printza N, Giapros V, Petropoulou F, Mitsioni A, Papachristou F, Stefanidis CJ, Pediatr Nephrol 2011 26 1105 1114 10.1007/s00467-011-1870-5 21479768
26. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, Juppner H, Salusky IB, J Clin Endocrinol Metab 2009 94 511 517 10.1210/jc.2008-0326 19050056
27. Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23? Wesseling-Perry K, Tsai EW, Ettenger RB, Juppner H, Salusky IB, Nephrol Dialysis Transplant 2011 26 3779 84 10.1093/ndt/gfr126
28. Are fibroblast growth factor 23 concentrations in renal transplant patients different from non-transplanted chronic kidney disease patients? Filler G, Liu D, Sharma AP, Grimmer J, Pediatr Transplant 2012 16 73 77 10.1111/j.1399-3046.2011.01613.x 22121948
29. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB, Kidney Int 2003 64 2272 2279 10.1046/j.1523-1755.2003.00328.x 14633152 (Pubitemid 37449564)